Renin-angiotensin system blockers and COVID-19

Vidal‐Petiot, Emmanuelle; Gault, Nathalie

doi:10.1186/s12916-021-02012-6

Cited by 3 publications

(3 citation statements)

References 10 publications

(17 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Based on these observations, it is not surprising that when the entire world was exposed to the outbreak of a new coronavirus disease (COVID-19), caused by the previously unknown human coronavirus SARS-CoV-2, the attention of researchers was also drawn to the role and balance of the RAS during this novel viral infection [ 35 , 36 , 37 , 38 , 39 , 40 ].…”

Section: The Ras and Viral Respiratory Infectionsmentioning

confidence: 99%

“…Since the beginning of the pandemic, many authors have speculated about the modulation of the RAS by SARS-CoV-2 based on the following: (i) the important role of the RAS in the pathological mechanisms of acute lung injury and ARDS; (ii) the key role of ACE2 receptor in viral entrance; and (iii) the proposed ability of rACE2 to reduce lung injury in SARS-CoV infection. It has also been proposed that alterations in the RAS could predict the outcome of the disease [ 35 , 36 , 37 , 38 , 39 ], which is based on the hypothesis that, at the serum level, there would have been the same RAS imbalance [ 46 , 47 ] observed at the tissue level [ 48 ].…”

Section: The Ras and Viral Respiratory Infectionsmentioning

confidence: 99%

See 1 more Smart Citation

The Renin–Angiotensin System (RAS) in COVID-19 Disease: Where We Are 3 Years after the Beginning of the Pandemic

Prato,

Tiberti,

Mazzi

et al. 2024

Microorganisms

View full text Add to dashboard Cite

The RAS is a hormonal system playing a pivotal role in the control of blood pressure and electrolyte homeostasis, the alteration of which is associated with different pathologies, including acute respiratory distress syndrome (ARDS). As such, it is not surprising that a number of studies have attempted to elucidate the role and balance of the renin–angiotensin system (RAS) in COVID-19. In this review article, we will describe the evidence collected regarding the two main enzymes of the RAS (i.e., ACE and ACE2) and their principal molecular products (i.e., AngII and Ang1-7) in SARS-CoV-2 infection, with the overarching goal of drawing conclusions on their possible role as clinical markers in association with disease severity, progression, and outcome. Moreover, we will bring into the picture new experimental data regarding the systemic activity of ACE and ACE2 as well as the concentration of AngII and Ang1-7 in a cohort of 47 COVID-19 patients hospitalized at the IRCCS Sacro Cuore-Don Calabria Hospital (Negrar, Italy) between March and April 2020. Finally, we will discuss the possibility of considering this systemic pathway as a clinical marker for COVID-19.

show abstract

Section: The Ras and Viral Respiratory Infectionsmentioning

confidence: 99%

Section: The Ras and Viral Respiratory Infectionsmentioning

confidence: 99%

The Renin–Angiotensin System (RAS) in COVID-19 Disease: Where We Are 3 Years after the Beginning of the Pandemic

Prato,

Tiberti,

Mazzi

et al. 2024

Microorganisms

View full text Add to dashboard Cite

show abstract

“…Despite this, ARBs were shown to be superior to ACEi in this category of patients, and treatment continuation has been proposed. However, other authors claimed that ACEi can be in fact benefic against pulmonary lesions induced by the virus and should be introduced in the treatment strategy of COVID-19 patients (49).…”

Section: Aldosteronementioning

confidence: 99%

Biomarkers of Volume Overload and Edema in Heart Failure With Reduced Ejection Fraction

Chiorescu

Lazar²,

Buksa³

et al. 2022

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

From a pathogenetic point of view, heart failure (HF) is characterized by the activation of several neurohumoral pathways with a role in maintaining the cardiac output and the adequate perfusion pressure in target organs and tissues. Decreased cardiac output in HF with reduced ejection fraction causes activation of the sympathetic nervous system, the renin angiotensin aldosterone system, arginine-vasopressin system, natriuretic peptides, and endothelin, all of which cause water and salt retention in the body. As a result, patients will present clinically as the main symptoms: dyspnea and peripheral edema caused by fluid redistribution to the lungs and/or by fluid overload. By studying these pathophysiological mechanisms, biomarkers with a prognostic and therapeutic role in the management of edema were identified in patients with HF with low ejection fraction. This review aims to summarize the current data from the specialty literature of such biomarkers with a role in the pathogenesis of edema in HF with low ejection fraction. These biomarkers may be the basis for risk stratification and the development of new therapeutic means in the treatment of edema in these patients.

show abstract

Molecular pathways involved in COVID-19 and potential pathway-based therapeutic targets

Farahani

Niknam

Amirabad

et al. 2022

Biomedicine & Pharmacotherapy

View full text Add to dashboard Cite

Renin-angiotensin system blockers and COVID-19

Cited by 3 publications

References 10 publications

The Renin–Angiotensin System (RAS) in COVID-19 Disease: Where We Are 3 Years after the Beginning of the Pandemic

The Renin–Angiotensin System (RAS) in COVID-19 Disease: Where We Are 3 Years after the Beginning of the Pandemic

Biomarkers of Volume Overload and Edema in Heart Failure With Reduced Ejection Fraction

Molecular pathways involved in COVID-19 and potential pathway-based therapeutic targets

Contact Info

Product

Resources

About